.Alnylam is suspending further advancement of a clinical-stage RNAi healing created to address Type ...
.Takeda has actually stopped (PDF) a stage 2 trial of danavorexton due to slow application, denoting...
.Compass Pathways' journey to stage 3 psychedelic anxiety records is actually taking much longer tha...
.After antibody-drug conjugate (ADC) expert Seagen was offered to Pfizer in 2015 for a monstrous $43...
.On the heels of a phase 3 gain that stopped working to blow away capitalists, Ironwood Pharmaceutic...
.Don't stop Monte Rosa Therapeutics currently. The Boston-based biotech is actually having a ball af...
.Invite to recently's Chutes & Ladders, our roundup of substantial management hirings, firings an...
.Commemorating his provider's upsized going public (IPO), Septerna chief executive officer Jeffrey F...
.AbbVie has returned to the resource of its own antipsychotic powerhouse Vraylar in search of an add...
.GenSight Biologics is actually full weeks away from losing cash. Again. The biotech merely has enou...
.Monopar Therapies is recuperating a drug coming from the scrap heap of AstraZeneca's unusual health...
.With new records out on Arcus Biosciences' speculative HIF-2a prevention, one team of professionals...
.After developing a genetics therapy alliance along with Dyno Rehabs in 2020, Roche is actually back...
.Lundbeck is actually reducing the book value of its $250 thousand Abide Therapeutics acquistion in ...
.The combination of real-world records (RWD) into protocol workability and website option has become...
.At this year's Intense Biotech Summit in Boston, our company caught up with leaders in the biotech ...
.Merck & Co. is setting down $30 million in advance to buy Yale spinout Modifi Biosciences, an of...
.Alpha-9 Oncology has actually raised a $175 thousand set C round to stake its clinical-stage radiop...
.Eye medicine creator Ocuphire Pharma is acquiring gene therapy creator Piece Genes in an all-stock ...
.Roche's severe cough plan has faltered to a standstill. The drugmaker, which axed the program after...